Eli Lilly and Company (BVMF:LILY34)

Market Cap	3.20T
Revenue (ttm)	290.19B
Net Income (ttm)	75.19B
Shares Out	n/a
EPS (ttm)	83.33
PE Ratio	42.51
Forward PE	23.64
Dividend	0.73 (0.61%)
Ex-Dividend Date	May 15, 2025

Volume	21,848
Average Volume	28,383
Open	116.40
Previous Close	115.11
Day's Range	116.11 - 119.00
52-Week Range	113.00 - 181.98
Beta	0.44
RSI	31.90
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD